Member Info for lagmassive

very clear that mm are short of shares

All 3 of my trades have not shown. Taken all day with mostly nt showing

https://www.youtube.com/watch?v=hnBfrY2PlmY&t

The additional footprint and automation come at a timely moment as demand for rapid tests is growing rapidly, with the market likely to exceed $10bn globally. Our precision automation and multi-site approach means we can adapt to meet the varying manufacturing needs of our growing global client base.”

https://www.technologynetworks.com/tn/news/abingdon-health-announces-expansion-and-additional-manufacturing-capacity-336491

.

Looks like the abbott and roche tests are s h i t e and the government are doing s h i t in unison with them. UK government are desperate for design freeze!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

https://www.stokesentinel.co.uk/news/stoke-on-trent-news/antibody-tests-royal-stoke-workers-4207550

Omega is now involved with five opportunities relating to Covid-19 testing, of which four utilise Mologic’s technology platforms, including the Covid-19 ELISA (enzyme-linked immunosorbent assay) which the company is already shipping.

Two are ELISA - lab based - tests, both antigen and antibody, and three are lateral flow, or rapid device, tests. Two of the lateral flow tests are in collaboration with Mologic and the third is an antibody test with UK Rapid Test Consortium as originally announced in April.

Colin King, Omega chief executive, said: “We are pleased that Omega has been able to widen its collaboration with Mologic which should help to expand the number of Covid-19 tests that can be run both in centralised and decentralised settings, which, along with our VISTECT CD4 tests, strengthens our position in global health.

The UK-RTC says it has made ‘significant progress’ in both developing the antibody test, as well as progress with the regulatory and logistics challenges needed to be able to deploy the test directly with individuals across the UK.

The company has shipped its first order for the COVID-19 ELISA test to Senegal worth £100,000 and is engaged in talks with 15 countries which is expected to lead to orders in the near future.

The antibody test will be able to help identify people that have built up immunity to coronavirus.

It hopes to manufacture up to 46,000 kits every day, equivalent to 16 million tests a year. The tests will be used on patient samples sent by hospitals or GPs for laboratory testing.

https://blog.primerdesign.co.uk/maximising-covid-19-capacity-at-primerdesign/

What the f--k are you lot talking about. Using charts in an attempt to convince others that you are the masters of where the price is going is total crap. Nothing but con men and thus scumbags. Chartiing is nothing more than fake voodoo. No ones got a clue what is gonna happen with the price tomorrow, any thing can happen. The fundamentals here speak for themselves and with that in mind only, strong buy at these prices.

Interferon is the key factor 7mins 30 seconds in

https://podcasts.jwatch.org/index.php/podcast-266-interferon-and-early-treatment-in-covid-19-bring-good-outcomes/2020/05/10/

Fact: patients really only improve when given Interferon 1b

https://podcasts.jwatch.org/index.php/podcast-266-interferon-and-early-treatment-in-covid-19-bring-good-outcomes/2020/05/10/

Leaks coming through

https://twitter.com/Space_Robot1/status/1259752173572952064?s=20

Interesting

https://twitter.com/Space_Robot1/status/1260261121715552256?s=20

Quality control (QC) review
National Library of Medicine (NLM) staff perform a limited review of submitted study records for apparent errors, deficiencies, or inconsistencies. NLM staff identify potential major and advisory issues and provide comments directly to the study sponsor or investigator. Major issues identified in QC review must be addressed or corrected (see First submitted that met QC criteria and Results first submitted that met QC criteria). Advisory issues are suggestions to help improve the clarity of the record. NLM staff do not verify the scientific validity or relevance of the submitted information. The study sponsor or investigator is responsible for ensuring that the studies follow all applicable laws and regulations.

https://clinicaltrials.gov/ct2/about-studies/glossary

Thanks kowalski, here it is summarised

https://noticias.r7.com/saude/coronavirus-estudo-com-coquetel-de-remedios-tem-bons-resultados-contra-a-covid-19-mostra-the-lancet-08052020

To date, early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.
https://www.thailandmedical.news/news/covid-19-drug-research-second-phase-of-clinical-trial-of-new-drug-candidate,-sng001-for-sars-cov-2-coronavirus-initiated

https://twitter.com/ProfWilko/status/1257060179746721792?s=20

https://twitter.com/UoSMedia/status/1255473196440190983?s=20

Prof Tom Wilkinson of
@UoS_Medicine
and
@RDsouthampton
will be clinical academic lead in a new national programme to accelerate the development of life-saving treatments for the most vulnerable #COVID19 patients.